Orris
attachment
attachment
attachment

Interpret

Reading File
Here is a comprehensive interpretation of all three documents for Mrs. Shashi Saxena, 68F:

📋 Summary of Clinical Picture

Diagnosis: Non-Small Cell Lung Cancer (NSCLC) — Adenocarcinoma of the Left Lung Molecular subtype: EGFR Exon-19 deletion positive Treatment initiated: Osimertinib (Tagrisso) 80 mg OD

🔬 Document 1 & 2: ¹⁸F-FDG Whole Body PET-CT Scan

(AIIMS Diagnostics, Jaipur | Date: 23/04/2026)

Primary Tumor (Thorax)

  • Intense FDG-avid (SUVmax 13.39), heterogeneously enhancing, ill-defined soft tissue mass in the left upper lobe, measuring ~36×33×53 mm
  • The lesion extends into the left hilum, encases the left main pulmonary artery and left main bronchus, causing near-complete collapse and consolidation of the left lung
  • This represents the known primary malignancy

Regional Lymph Node Involvement (N-stage)

  • FDG-avid left supraclavicular lymph node (SUVmax 8.59, ~20×15 mm) — likely metastatic
  • Mediastinal lymph nodes involved: para-aortic, bilateral lower para-tracheal, subcarinal (~30×23 mm, SUVmax 8) and bilateral hilar regions — likely metastatic disease
  • This corresponds to at least N3 disease (contralateral/supraclavicular nodal spread)

Pleural Involvement

  • Loculated moderate-to-gross left pleural effusion with passive collapse and consolidation of the left lung — indicating pleural involvement (M1a in staging)

Head & Neck

  • Increased FDG uptake in nape of neck (SUVmax 6.66) — likely infective/inflammatory, not metastatic
  • No significant FDG-avid cervical lymphadenopathy

Brain

  • No abnormal metabolically active lesion seen
  • ⚠️ Important caveat: Brain metastases may not be detectable on FDG PET/CT — MRI brain is recommended if clinically suspected

Abdomen & Pelvis

  • Bulky uterus (likely fibroid/age-related, clinically correlate)
  • Liver, spleen, pancreas, kidneys, adrenals — all normal, no metastatic deposits
  • No skeletal (bone) metastases

Musculoskeletal

  • Age-related degenerative changes and osteophytes in dorsolumbar vertebrae — no FDG-avid skeletal metastases

PET-CT Staging Summary

ParameterFinding
TT3–T4 (large mass >5 cm, encasing PA & bronchus)
NN3 (ipsilateral mediastinal + left supraclavicular nodes)
MM1a (malignant pleural effusion)
Overall StageStage IIIB–IVA

💊 Document 3: Prescription from Suvira Hospital

(Dr. Puneet Gupta, Sr. Consultant Internal Medicine | Date: 18/05/2026)
Referral to: Dr. Pulkit Nag (likely medical oncologist)
Diagnosis noted: K/C/O Adeno-Ca Lung (Known case of Adenocarcinoma Lung)
Molecular finding:
  • EGFR Exon-19 deletion — a sensitizing/activating mutation, present in ~45% of EGFR-mutant NSCLC cases
Treatment prescribed:
Tab. Osimertinib (Tagrisso) 80 mg — Once Daily × 30 days

🧬 Clinical Interpretation & Significance

Why Osimertinib?

Osimertinib (Tagrisso) is a 3rd-generation EGFR tyrosine kinase inhibitor (TKI) and is the standard first-line treatment for EGFR-mutant advanced NSCLC (FLAURA trial evidence). It:
  • Targets EGFR Exon-19 deletions and Exon-21 L858R mutations
  • Also penetrates the blood-brain barrier, offering CNS protection (important given the PET-CT note about brain lesions potentially being missed)
  • Is oral, once-daily, generally well-tolerated

Key Clinical Concerns for This Patient

  1. Large left lung primary with complete left lung collapse — symptom burden likely high (dyspnea, reduced breath sounds on left)
  2. Left pleural effusion — may need therapeutic thoracocentesis for symptom relief
  3. Left supraclavicular + mediastinal nodal disease — Stage IVA, systemic therapy (Osimertinib) is the correct approach
  4. Brain metastasis risk — PET-CT cannot rule out micro-metastases; MRI brain is strongly recommended (as noted in the report)
  5. Bulky uterus — needs gynecologic correlation; not related to current malignancy based on PET findings

✅ Bottom Line

Mrs. Shashi Saxena has Stage IVA EGFR-mutant (Exon-19 del) lung adenocarcinoma with:
  • Bulky left upper lobe primary mass causing lobar collapse
  • Malignant left pleural effusion
  • Nodal metastases (mediastinal + left supraclavicular)
  • No distant organ metastases on PET-CT (brain not fully assessable by PET)
She has been appropriately started on Osimertinib 80 mg OD — the current standard of care per NCCN/ESMO guidelines for first-line EGFR-mutant NSCLC. Ongoing monitoring should include MRI brain, pulmonary function assessment, and response evaluation PET-CT after ~3 months.
This is a shared conversation. Sign in to Orris to start your own chat.